The successful use of tocilizumab as third-line biologic therapy in a case of refractory anti-synthetase syndrome

Sean M Murphy; James B Lilleker; Philip Helliwell; Hector Chinoy

doi:10.1093/rheumatology/kew296

The successful use of tocilizumab as third-line biologic therapy in a case of refractory anti-synthetase syndrome

Sean M Murphy, James B Lilleker, Philip Helliwell, Hector Chinoy

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	2277-2278
Number of pages	2
Journal	Rheumatology (Oxford, England)
Volume	55
Issue number	12
Early online date	Aug 2016
DOIs	https://doi.org/10.1093/rheumatology/kew296
Publication status	Published - Dec 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/rheumatology/kew296

Cite this

@article{cff57479ce8044fc81c9927a0527c728,

title = "The successful use of tocilizumab as third-line biologic therapy in a case of refractory anti-synthetase syndrome",

author = "Murphy, \{Sean M\} and Lilleker, \{James B\} and Philip Helliwell and Hector Chinoy",

year = "2016",

month = dec,

doi = "10.1093/rheumatology/kew296",

language = "English",

volume = "55",

pages = "2277--2278",

journal = "Rheumatology (Oxford, England)",

issn = "1462-0324",

publisher = "Oxford University Press",

number = "12",

}

TY - JOUR

T1 - The successful use of tocilizumab as third-line biologic therapy in a case of refractory anti-synthetase syndrome

AU - Murphy, Sean M

AU - Lilleker, James B

AU - Helliwell, Philip

AU - Chinoy, Hector

PY - 2016/12

Y1 - 2016/12

UR - https://www.scopus.com/pages/publications/85019888474

U2 - 10.1093/rheumatology/kew296

DO - 10.1093/rheumatology/kew296

M3 - Article

C2 - 27550295

SN - 1462-0324

VL - 55

SP - 2277

EP - 2278

JO - Rheumatology (Oxford, England)

JF - Rheumatology (Oxford, England)

IS - 12

ER -

The successful use of tocilizumab as third-line biologic therapy in a case of refractory anti-synthetase syndrome

UN SDGs

Access to Document

Other files and links

MMRG: Manchester Myositis Research Group

Cite this

The successful use of tocilizumab as third-line biologic therapy in a case of refractory anti-synthetase syndrome

UN SDGs

Access to Document

Other files and links

Projects

MMRG: Manchester Myositis Research Group

Cite this